[Clinical treatment of chronic psychoses with flupenthixol-decanoate (Fluanxol-Depot)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D000431:Ethanol / Q000627:therapeutic use; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014966:Xanthenes / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D010879:Piperazines; D014149:Tranquilizing Agents; D014966:Xanthenes; D000431:Ethanol
Klinische Erfahrungen mit Flupenthixol-Decanoat (Fluanxol-Depot) bei chronischen Psychosen.